Jacky Vonderscher
Co-founder & Chief Executive Officer Enyo Pharma
Seminars
Tuesday 17th March 2026
A Novel Potential Therapy for Alport Syndrome with Applicability in Multiple Rare & Common Renal Diseases
4:00 pm
- Phase 2 “ALPESTRIA-1” trial demonstrated significantly reduced albuminuria and reversed the expected decline in kidney function with durable effects after treatment discontinuation in Alport syndrome
- Targeted effects on inflammation and fibrosis, downstream of causal mutational changes and hallmarks of most CKD, may be relevant for other diseases such as ADPKD
- A third trial, in CKD/DKD associated with MASH, studies a new indication opportunity for fast-follower compound EYP651
